Home Ingredients AB-Fortis® (Microencapsulated Iron — Frutarom)
Energy

AB-Fortis® (Microencapsulated Iron — Frutarom)

Evidence Level
Moderate
1 Clinical Trial
6 Documented Benefits
3/5 Evidence Score

AB-Fortis® is a microencapsulated form of iron developed by Frutarom Health (now IFF) — designed to fortify foods with iron without changing appearance, palatability, or taste. Distinguished by encapsulation technology that addresses iron's primary fortification challenges (metallic taste, color changes, GI side effects). Used for: iron deficiency replacement, anemia adjunct, food fortification, supplementation with improved palatability.

Studied Dose Per AB-Fortis product specification (typical 8-18 mg elemental iron/day)
Active Compound Microencapsulated iron

Benefits

Iron Deficiency Replacement

Iron is essential for hemoglobin synthesis, oxygen transport, and energy metabolism, and AB-Fortis delivers absorbable iron to help correct an iron deficiency. Iron corrects fatigue and low energy only in people who are genuinely iron-deficient, not in those who are already iron-replete. The published AB-Fortis evidence is delivery and bioavailability technology rather than clinical anemia trials, so the underlying clinical benefit is iron the nutrient itself.

Supported by Trial 1

Improved Palatability

Encapsulation eliminates metallic taste of standard iron supplements — major improvement; particularly relevant for prenatal vitamins, multivitamins, pediatric formulations.

Supported by Trial 1

Food Fortification Without Sensory Changes

Suitable for fortifying foods (cereals, baked goods, beverages) without changing appearance, taste, or color.

Supported by Trial 1

Reduced Oxidation

Encapsulation reduces iron oxidation in food matrices and during digestion.

Supported by Trial 1

Reduced GI Side Effects

May reduce iron-related GI side effects (constipation, nausea) common with standard iron.

Supported by Trial 1

Less fatigue when iron stores are low (ferrous sulfate trials)

Studied as ordinary oral ferrous sulfate at 80 mg iron a day, not AB-Fortis. In two placebo-controlled trials of non-anemic women with fatigue, scores fell 29% vs 13% after 4 weeks (144 women) and 47.7% vs 28.8% after 12 weeks (198 women, ferritin under 50 ug/L). Gains were limited to low ferritin; a pooled analysis of 6 trials in iron deficiency without anemia also found less fatigue. AB-Fortis is listed at a far lower 8 to 18 mg/day.

Supported by Trial 1

Mechanism of action

1

Iron Hemoglobin Function

Iron is essential cofactor in hemoglobin and myoglobin; deficiency causes microcytic anemia.

2

Iron Energy Metabolism

Iron is cofactor for cytochromes in mitochondrial electron transport — relevant to energy production.

3

Microencapsulation

Protects iron through GI tract; releases at appropriate location for absorption; reduces interaction with food matrix.

Clinical trials

1
AB-Fortis Bioavailability Studies — Frutarom

Frutarom evaluation of AB-Fortis iron bioavailability and food-fortification performance. Note: the cited evidence is delivery/bioavailability and sensory technology, not a clinical anemia efficacy trial.

Adults including iron-deficient populations.

Bioavailability suitable for iron deficiency replacement; improved palatability vs unencapsulated iron.

Side effects and drug interactions

Common Potential side effects

Generally well-tolerated; encapsulation reduces standard iron side effects.
Mild GI distress, constipation possible (less than standard iron).
Dark stool (normal with iron).
Iron overload concern — never supplement iron without confirmed need due to hemochromatosis risk. Keep all iron-containing products out of reach of children: iron is a leading cause of fatal poisoning in young children, and accidental overdose can be life-threatening — seek emergency care immediately if a child ingests iron supplements.

Important Drug interactions

Levothyroxine — iron reduces absorption; separate by 4 hours.
Fluoroquinolones, tetracyclines — iron reduces absorption; separate by 2 hours.
Calcium supplements — calcium reduces iron absorption; separate timing.
Zinc supplements — competition for absorption; separate timing.
PPIs / antacids — reduced gastric acid impairs iron absorption.
Vitamin C — enhances non-heme iron absorption (positive interaction).
Pregnancy — iron deficiency common; supplementation often appropriate; consult prenatal care.
Hemochromatosis — avoid iron supplementation in this condition.

Featured in these supplement guides

Low Iron & Anemia Support→

More Energy Ingredients

Energy
Caffeine
Caffeine is a stimulant found naturally in coffee, tea, cocoa, guarana and kola nut, added…
Energy
Iron
Iron is an essential mineral needed to make hemoglobin, the protein in red blood cells tha…
Energy
Ferrous Sulfate
Ferrous sulfate is the reference oral iron salt, the form that most other iron supplements…
Energy
Vitamin B12
Vitamin B12 (cobalamin) is a water-soluble vitamin needed for red blood cell formation, DN…

Explore Other Ingredients

Antioxidant
Milk Thistle
Milk thistle (Silybum marianum) supplies silymarin, a mix of plant compounds called flavon…
Antioxidant
NAC (N-Acetylcysteine)
N-acetylcysteine (NAC) is a modified form of the amino acid cysteine. The body uses cystei…
Dandelion Root
Dandelion root is the root of the common dandelion (Taraxacum officinale), a plant used as…

Frequently asked questions about AB-Fortis® (Microencapsulated Iron — Frutarom)

What is AB-Fortis?

AB-Fortis® is a microencapsulated form of iron developed by Frutarom Health (now IFF) — designed to fortify foods with iron without changing appearance, palatability, or taste.

What is AB-Fortis used for?

AB-Fortis is researched primarily for Energy. Iron is essential for hemoglobin synthesis, oxygen transport, and energy metabolism, and AB-Fortis delivers absorbable iron to help correct an iron deficiency.

What is the recommended dosage of AB-Fortis?

The clinically studied dose is Per AB-Fortis product specification (typical 8-18 mg elemental iron/day) Always follow the product label and check with a healthcare provider for personal advice.

Is AB-Fortis safe, and does it have side effects?

Side effects and cautions reported for AB-Fortis include: Generally well-tolerated; encapsulation reduces standard iron side effects. Mild GI distress, constipation possible (less than standard iron). It may also interact with some medications. AB-Fortis is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does AB-Fortis interact with any medications?

Possible interactions include: Levothyroxine — iron reduces absorption; separate by 4 hours. Fluoroquinolones, tetracyclines — iron reduces absorption; separate by 2 hours. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for AB-Fortis?

NutraSmarts rates the evidence for AB-Fortis as Moderate (3 out of 5). It is backed by 1 study summary and 6 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(6 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Mehansho H Iron fortification technology development: new approaches The Journal of Nutrition. 2006;136(4):1059-63. doi: 10.1093/jn/136.4.1059.PubMedUsed to support: Review documenting encapsulation, chelation, and redox-modulation approaches to iron fortification showing that these methods eliminate detrimental effects on taste, color, and product stability while maintaining bioavailability and reducing iron deficiency anemia in human intervention trials. Supports Improved Palatability, Food Fortification Without Sensory Changes, and Reduced Oxidation benefits. Study covers the compound class/technology rather than the AB-Fortis brand specifically.
  2. Kongkachuichai R, Kounhawej A, Chavasit V, Charoensiri R Effects of various iron fortificants on sensory acceptability and shelf-life stability of instant noodles Food and Nutrition Bulletin. 2007;28(2):165-72. doi: 10.1177/156482650702800205.PubMedUsed to support: Comparative study of iron fortification forms in food showing that iron compound choice critically affects sensory acceptability and color stability. Supports the Food Fortification Without Sensory Changes benefit by providing evidence for the importance of encapsulation in food-grade iron applications. Study is on iron compounds generally, not the AB-Fortis brand.
  3. Gotelli CA, Gotelli MJ, Boccio JR, Zubillaga MB, Caro RA, García del Río H, Weill R Bioavailability of microencapsulated ferrous sulfate in fluid milk studies in human beings Acta Physiologica, Pharmacologica et Therapeutica Latinoamericana. 1996;46(4):239-45..PubMedUsed to support: Human bioavailability study (n=29) showing microencapsulated ferrous sulfate (soy-lecithin-coated, SFE-171) in fortified milk achieved 10.2% average iron absorption without affecting sensory qualities. Supports Iron Deficiency Replacement and Improved Palatability benefits with human evidence. Study is on microencapsulated ferrous sulfate as a compound class, not the AB-Fortis brand specifically.
  4. Vaucher P, Druais PL, Waldvogel S, Favrat B. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ. 2012;184(11):1247-54..PubMedUsed to support: Multicentre RCT: 198 non-anemic women with fatigue and ferritin under 50 ug/L took oral ferrous sulfate (80 mg elemental iron/day) or placebo for 12 weeks. Fatigue fell 47.7% vs 28.8% (difference -18.9%, p=0.02), with no effect on quality of life, depression or anxiety. Studied ferrous sulfate, not AB-Fortis. Supports the fatigue benefit for low iron stores.
  5. Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, Bischoff T, de Vevey M, Studer JP, Herzig L, Chapuis C, Tissot J, Pécoud A, Favrat B. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ. 2003;326(7399):1124..PubMedUsed to support: Double-blind RCT: 144 non-anaemic women took oral ferrous sulphate (80 mg elemental iron/day) or placebo for 4 weeks. Fatigue fell 29% vs 13% (p=0.004), and only women with ferritin of 50 ug/L or less improved. Studied ferrous sulphate, not AB-Fortis. Supports the fatigue benefit for low iron stores.
  6. Yokoi K, Konomi A. Iron deficiency without anaemia is a potential cause of fatigue: meta-analyses of randomised controlled trials and cross-sectional studies. Br J Nutr. 2017;117(10):1422-1431..PubMedUsed to support: Meta-analysis of 6 RCTs of iron in fatigued people with iron deficiency without anaemia: pooled effect size 0.33 (95% CI 0.17 to 0.48, I2=0%). Iron forms and routes are not given in the abstract and none is AB-Fortis. Supports the 'pooled analysis of 6 trials' statement.